Company / Free Cash Flow
Supernus Pharmaceuticals, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$46.0M
FY2025
5-year range
$46.0M / $171.2M
FY2021-FY2025
Trend
-73.1%
vs FY2024
Sector context
#54 of 194
Health Care
What the data says
At $46M, Supernus Pharmaceuticals, Inc.'s free cash flow ranks #54 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 9 years, ranging from -$25M in FY2016 to $171M in FY2024.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of -19.4%.
Declined from $111M to $46M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -26.6%
- 5-Year CAGR
- -19.4%
- 10-Year CAGR
- -
Sector benchmark
#54 of 194 in Health CareTop 28% of 194This company $46.0M Sector average $470.6M
▼
-90.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -19.4%, indicating a declining trend.
- In FY2025, free cash flow decreased 73.1% year-over-year.
- Ranks #54 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $46.0M | -73.1% |
| FY2024 | $171.2M | +54.9% |
| FY2023 | $110.5M | -5.1% |
| FY2022 | $116.4M | - |
| FY2021 | - | - |
| FY2020 | $134.9M | -3.9% |
| FY2019 | $140.4M | +115.3% |
| FY2018 | $65.2M | +101.1% |
| FY2017 | $32.4M | +229.2% |
| FY2016 | -$25.1M | -177.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026